| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5658590 | LILLY | Treatment of attention-deficit/hyperactivity disorder |
Nov, 2016
(7 years ago) | |
|
US5658590 (Pediatric) | LILLY | Treatment of attention-deficit/hyperactivity disorder |
May, 2017
(6 years ago) | |
Strattera is owned by Lilly.
Strattera contains Atomoxetine Hydrochloride.
Strattera has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Strattera are:
- US5658590
- US5658590*PED
Strattera was authorised for market use on 26 November, 2002.
Strattera is available in capsule;oral dosage forms.
Strattera can be used as treatment of attention-deficit hyperactivity disorder.
The generics of Strattera are possible to be released after 26 May, 2017.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-78) | Jul 23, 2011 |
Drugs and Companies using ATOMOXETINE HYDROCHLORIDE ingredient
Market Authorisation Date: 26 November, 2002
Treatment: Treatment of attention-deficit hyperactivity disorder
Dosage: CAPSULE;ORAL
How can I launch a generic of STRATTERA before it's drug patent expiration?
More Information on Dosage
STRATTERA family patents
